| Derivation cohort (n = 35) | Validation cohort (n = 123) | p value |
---|---|---|---|
Follow-up (years) | 4.3 ± 1.9 | 3.4 ± 2.3 | 0.02* |
Age, (years) | 63 ± 18 | 68 ± 16 | 0.12 |
Male, no (%) | 18 (51) | 60 (49) | 0.70 |
Comorbidities, no. (%) | Â | Â | Â |
 Atrial fibrillation | 8 (23) | 29 (24) | 1.00 |
 Diabetes | 9 (26) | 25 (20) | 0.49 |
 Heart Failure | 2 (9) | 21 (17) | 0.11 |
 Hypercholesterolemia | 13 (37) | 22 (18) | 0.02* |
 Ischaemic heart disease | 7 (20) | 34 (28) | 0.51 |
 Malignancy | 8 (23) | 18 (15) | 0.13 |
 Stroke | 4 (11) | 3 (2) | 0.04* |
 Charlson’s Comorbidity Index (CCI) Score | 1.5 ± 1.8 | 1.6 ± 1.9 | 0.79 |
Clinical Outcomes | Â | Â | Â |
 Day 1 PASP, (mmHg) | 33 ± 8 | 41 ± 16 | 0.006* |
 Simplified PESI score | 0.9 ± 0.9 | 0.9 ± 1.0 | 0.88 |
 Recurrent PE, no (%) | 7 (20) | 9 (7) | 0.05 |
 Death, no (%) | 10 (29) | 37 (30) | 1.00 |